Aarey Drugs & Pharmaceuticals Ltd

Surging to a new 52-week high of Rs 104.1 on 21 Sep 2026, Aarey Drugs & Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market over the past year.

Surging to a fresh 52-week high of Rs 102.99 on 18 Sep 2026, Aarey Drugs & Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market over the past year.

Surging past Rs 101.84 on 17 Sep 2026, Aarey Drugs & Pharmaceuticals Ltd has marked a significant milestone by reaching a fresh 52-week high. This achievement caps a remarkable 43.23% rally over the past year, substantially outperforming the Sensex’s decline of 10.11% during the same period.

Surging to a new 52-week high of Rs 101.13 on 16 Sep 2026, Aarey Drugs & Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a challenging environment for the Sensex.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging past the Rs 100 mark for the first time in 52 weeks, Aarey Drugs & Pharmaceuticals Ltd has demonstrated remarkable price momentum, climbing from a low of Rs 50.40 to Rs 101.11 in the past year. This 36.68% gain stands in stark contrast to the Sensex’s 8.15% decline over the same period, underscoring the stock’s resilience amid a broadly challenging market environment.

At Rs 89.01, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Aarey Drugs & Pharmaceuticals Ltd locked at its upper circuit of 4.99% on 28 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 August 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 84.78, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Aarey Drugs & Pharmaceuticals Ltd locked at its upper circuit of 4.9% on 27 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 80.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Aarey Drugs & Pharmaceuticals Ltd locked at its upper circuit of 5% on 26 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Aarey Drugs & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a downgrade in its overall Mojo Grade to Sell. This nuanced change reflects evolving market perceptions amid mixed financial metrics and a challenging industry backdrop, offering investors a fresh perspective on the stock’s price attractiveness relative to peers and historical benchmarks.

Aarey Drugs & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite lingering concerns over profitability and market positioning. This micro-cap pharmaceutical player’s recent price movements and valuation metrics warrant a closer examination to understand the evolving price attractiveness and what it means for investors navigating the Pharmaceuticals & Biotechnology sector.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with the latest insights into the company’s performance and outlook.